[1]唐茂盛 肖萌萌 陈小兵 邹博远 李文杰 罗成华*.腹膜后恶性外周神经鞘瘤的临床特征及外科诊治分析[J].中国微创外科杂志,2022,01(12):966-9970.
　Tang Maosheng,Xiao Mengmeng,Chen Xiaobing,et al.Clinical Features and Surgical Diagnosis and Treatment of Retroperitoneal Malignant Peripheral Nerve Sheath Tumor[J].Chinese Journal of Minimally Invasive Surgery,2022,01(12):966-9970.
点击复制

腹膜后恶性外周神经鞘瘤的临床特征及外科诊治分析()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
01
期数:
2022年12期
页码:
966-9970
栏目:
临床研究
出版日期:
2023-03-13

文章信息/Info

Title:
Clinical Features and Surgical Diagnosis and Treatment of Retroperitoneal Malignant Peripheral Nerve Sheath Tumor
作者:
唐茂盛 肖萌萌 陈小兵 邹博远 李文杰 罗成华*
(北京大学国际医院腹膜后肿瘤外科，北京102206)
Author(s):
Tang Maosheng;  Xiao Mengmeng;  Chen Xiaobing;  et al.
Department of Retroperitoneal Tumors, Peking University International Hospital, Beijing 102206, China
关键词:
恶性外周神经鞘瘤; 腹膜后肿瘤
Keywords:
Malignant peripheral nerve sheath tumor; Retroperitoneal neoplasms
文献标志码:
A
摘要:
目的探讨腹膜后恶性外周神经鞘瘤的临床特征及外科诊治疗效。方法回顾性分析2015年4月~2021年10月16例腹膜后恶性外周神经鞘瘤的临床资料。散发性12例，继发于Ⅰ型神经纤维瘤病4例。肿瘤单发13例，多发3例。肿瘤最大径5~30 cm，(16.53±7.12)cm，其中13例≥10 cm。5例包绕重要血管。均行手术切除。结果完整切除10例，姑息性切除6例。联合脏器切除6例。分块切除5例。术中出血量100~6000 ml，中位数2000 ml。术后并发症6例，死亡1例。16例中位生存期24个月。完整切除10例中位生存期25.0月，姑息性切除6例中位生存期14.0月。结论腹膜后恶性外周神经鞘瘤恶性程度高，侵袭性强，手术治疗困难。
Abstract:
ObjectiveTo explore the clinical features and surgical efficacy for retroperitoneal malignant peripheral nerve sheath tumors.MethodsClinical data of 16 cases of retroperitoneal malignant peripheral nerve sheath tumor from April 2015 to October 2021 were retrospectively analyzed. There were 12 cases of sporadic disease and 4 cases secondary to type Ⅰ neurofibromatosis. There were 13 cases of single tumor and 3 cases of multiple tumors. The maximum diameter of tumor was 5-30 cm (mean, 16.53±7.12 cm), 13 of which were≥10 cm. The tumor surrounded important blood vessels in 5 cases. All the patients underwent surgical resection.ResultsThere were 10 cases of complete resection and 6 cases of palliative resection. There were 6 cases of combined organ resection. The tumor was resected in blocks in 5 cases. The intraoperative blood loss was 100-6000 ml (median, 2000 ml). There were 6 cases of postoperative complications. One patient died. The median survival of the 16 cases was 24 months, which was 25.0 months in the 10 patients with complete resection and 14.0 months in the 6 patients with palliative resection.ConclusionRetroperitoneal malignant peripheral nerve sheath tumors are highly malignant and aggressive, which are difficult to treat surgically.

参考文献/References:

[1]Zehou O,Fabre E,Zelek L,et al.Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1:a 10year institutional review.Orphanet J Rare Dis,2013,8:127.
[2]李琛,张智弘,潘敏鸿,等.恶性外周神经鞘瘤52例临床病理分析.临床与实验病理学杂志,2016,32(6):644-647.
[3]Doyle LA.Sarcoma classification:an update based on the 2013 World Health Organization classification of tumors of soft tissue and bone.Cancer,2014,120(12):1763-1774.
[4]袁振南,徐立斌,赵振国,等.140例恶性外周神经鞘瘤患者的临床病理特征与预后分析.中华肿瘤杂志,2017,39(6):439-444.
[5]Hsu CC,Huang TW,Hsu JY,et al.Malignant peripheral nerve sheath tumor of the chest wall associated with neurofibromatosis:a case report.J Thorac Dis,2013,5(3):E78-82.
[6]Mavrogenis AF,Pala E,Guerra G,et al.Malignant peripheral nerve sheath tumor:models,biology,and translation.Oncogene,2022,41(17):2405-2421.
[7]李雪莹,罗宁,董洋.恶性外周神经鞘瘤的影像特征与临床分析.临床放射学杂志,2020,39(2):377-381.
[8]张笑盈,任玉波,杨绍敏,等.腹膜后恶性外周神经鞘膜瘤13例临床病理分析.临床与实验病理学杂志,2018,34(6):627-631.
[9]李琛,张智弘,潘敏鸿,等.恶性外周神经鞘瘤52例临床病理分析.临床与实验病理学杂志,2016,32(6):644-647.
[10]王坚,朱雄增.软组织肿瘤病理学.第2版.北京：人民卫生出版社,2017.1093-1113.
[11]Porter DE,Prasad V,Foster L,et al.Survival in malignant peripheral nerve sheath tumours:a comparison between sporadic and neurofibromatosis type 1associated tumours.Sarcoma,2009,2009：756395.
[12]LaFemina J,Qin LX,Moraco NH,et al.Oncologic outcomes of sporadic,neurofibromatosisassociated,and radiationinduced malignant peripheral nerve sheath tumors.Ann Surg Oncol,2013,20(1):66-72.
[13]Sharma MR,Puj KS,Salunke AA,et al.Malignant peripheral nerve sheath tumor with analysis of various prognostic factors:a singleinstitutional experience.J Cancer Res Ther,2021,17(1):106-113.
[14]Higham CS,Steinberg SM,Dombi E,et al.SARC006:phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 associated chemotherapynaive malignant peripheral nerve sheath tumors.Sarcoma,2017,2017:8685638.
[15]Valentin T,Le Cesne A,RayCoquard I,et al.Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSFGETO).Eur J Cancer,2016,56:77-84.
[16]Bishop AJ,Zagars GK,Torres KE,et al.Malignant peripheral nerve sheath tumors: a single institution’s experience using combined surgery and radiation therapy.Am J Clin Oncol,2018,41(5):465-470.

备注/Memo

备注/Memo:
*通讯作者，Email：luochenghua@pkuih.edu.cn
更新日期/Last Update: 2023-03-13